Bain Capital Life Sciences Investors’s Centessa Pharmaceuticals CNTA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-635,000	Closed	-$25.2M	–	22
2026 Q1	$25.2M	Buy	+635,000	New	+$16.2M	2.27%	12

Bain Capital Life Sciences Investors's CNTA Position: Q2 2026 in Review

Bain Capital Life Sciences Investors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 635,000 shares — an estimated $25.2M sold.

Bain Capital Life Sciences Investors first reported a position in CNTA in Q1 2026 and held it in 1 quarter. The position peaked at $25.2M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Bain Capital Life Sciences Investors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 635,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $25.2M.
Bain Capital Life Sciences Investors first reported a position in Centessa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Bain Capital Life Sciences Investors's Centessa Pharmaceuticals position peaked at $25.2M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.